文献速递甲状腺疾病

Lonigutamab通过降低IGF-1R水平抑制甲状腺眼病眶成纤维细胞透明质酸产生

Lonigutamab Inhibits Hyaluronan Production by Reducing IGF-1R Levels in Thyroid Eye Disease Orbital Fibroblasts.
PubMed 文献 · J Clin Endocrinol Metab · 2026-07-27

本研究在甲状腺眼病(TED)患者眶成纤维细胞(OFs)中评估新一代抗IGF-1R单抗lonigutamab对透明质酸(HA)产生的影响及机制。结果显示lonigutamab显著减少基础和IGF-1诱导的HA产生,并通过促进IGF-1R内化及蛋白酶体和溶酶体途径降解降低成熟IGF-1R蛋白水平,呈时间和剂量依赖性。结论提示lonigutamab可能通过高效降解IGF-1R抑制HA产生,支持其作为TED潜在治疗选择。

要点

  • Lonigutamab显著减少TED OFs基础和IGF-1诱导的HA产生。
  • Lonigutamab促进IGF-1R内化并经蛋白酶体和溶酶体途径降解。
  • Lonigutamab降低成熟IGF-1R蛋白水平呈时间和剂量依赖性。

核心结论

  • Lonigutamab通过高效内化和降解IGF-1R抑制TED OFs的HA产生,支持其独特作用机制和作为TED治疗选择的潜力。

研究设计与样本

  • 实验研究:使用TED患者眶成纤维细胞(OFs),在有或无IGF-1条件下给予lonigutamab处理。
  • 采用ELISA和琼脂糖凝胶电泳检测HA,流式细胞术和Western blot评估IGF-1R水平。
  • 使用蛋白酶体抑制剂MG132和溶酶体/自噬抑制剂bafilomycin探究lonigutamab介导的降解途径。

主要发现

  • Lonigutamab显著降低所有评估的TED OFs菌株的基础和IGF-1诱导的HA产生。
  • Lonigutamab以时间和剂量依赖方式降低成熟IGF-1R蛋白水平。
  • Lonigutamab促进IGF-1R内化,并通过蛋白酶体和溶酶体途径促进其降解。

临床怎么用

  • Lonigutamab可能作为TED的靶向治疗选择,通过降解IGF-1R减少HA沉积。
  • 需进一步临床研究验证lonigutamab在TED患者中的疗效和安全性。

局限性

  • 研究仅使用TED OFs进行体外实验,未涉及体内或临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In thyroid eye disease (TED), the connective tissue behind the eye becomes inflamed and expands, partly due to excessive deposition of hyaluronan (HA), which absorbs water, leading to osmotic swelling. Orbital fibroblasts (OFs) from patients with TED overexpress insulin-like growth factor 1 receptor (IGF-1R), a receptor that promotes cell survival, proliferation, and HA production. These processes contribute to orbital tissue remodeling and expansion, as well as to the inflammation and fibrosis characteristic of TED. Therapeutic options remain limited, highlighting the need for additional targeted therapies. Lonigutamab is a next-generation anti-IGF-1R monoclonal antibody that binds to a distinct epitope on IGF-1R with high affinity, eliciting a novel mechanism of action. OBJECTIVE: To evaluate whether lonigutamab inhibits HA production and characterize its mechanism of action using TED OFs. METHODS: TED OFs were treated with lonigutamab in the presence or absence of IGF-1. HA was measured by ELISA and agarose gel electrophoresis. IGF-1R levels were assessed by flow cytometry and Western blot. The proteasome inhibitor MG132 and the lysosome/autophagy inhibitor bafilomycin were used to probe lonigutamab-mediated degradation pathways. RESULTS: Lonigutamab significantly reduced basal and IGF-1-induced HA production across all evaluated TED OF strains. Lonigutamab also decreased mature IGF-1R protein levels in a time- and dose-dependent manner by promoting IGF-1R internalization and subsequent degradation through proteasomal and lysosomal pathways. CONCLUSIONS: These findings suggest that lonigutamab suppresses HA production in TED OFs via efficient IGF-1R internalization and degradation, supporting its unique mechanism of action and potential as a therapeutic option for TED.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Roztocil E, Husain F, Patrick CC, et al. Lonigutamab Inhibits Hyaluronan Production by Reducing IGF-1R Levels in Thyroid Eye Disease Orbital Fibroblasts. J Clin Endocrinol Metab. 2026. PMID: 42504937. doi:10.1210/clinem/dgag299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。